Skip to content
AnalystLens

HALO · Halozyme Therapeutics

297 filings

8-K

HALO 8-K Current Reports

Halozyme Therapeutics - 297 current reports

Filing record · 2016–202610-K1110-Q338-K141

HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Mar ’18Mar ’18
  2. FY2019 annual report10-K · Feb ’20Feb ’20
  3. Deal closed8-K · May ’22May ’22
  4. Leadership change8-K · Dec ’25Dec ’25
Showing 1-50 of 297 filings
8-K
Earnings & ResultsExhibits & Filings

Halozyme Therapeutics 8-K Report, Financial Results (Nov 5, 2026)

Halozyme Therapeutics reported a strong third quarter of 2026, with total revenue growing 39% year-over-year to $493 million and royalty revenue increasing by 44% to $341 million. This robust performance has prompted the company to raise its full-year 2026 financial guidance across key metrics including total revenue, royalty revenue, Adjusted EBITDA, and Non-GAAP Diluted EPS. The company also highlighted significant progress in its ENHANZE® collaboration agreements, expanding partnerships with three current collaborators and advancing three ENHANZE® programs into Phase 1 clinical development. A notable legal victory was also achieved, with a Dutch patent court ruling in favor of Halozyme in an infringement case against Merck concerning its Keytruda Qlex product, leading to an injunction in several European markets. The company further strengthened its financial position by completing a $1.5 billion convertible notes offering.

Nov 5, 2026
8-K
Leadership Changes

Halozyme Therapeutics 8-K Report, Executive Changes (Sep 30, 2026)

Halozyme Therapeutics, Inc. filed this Form 8-K to report under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers) that James Daly was elected to the Board of Directors on September 28, 2026. Mr. Daly was elected to the class of directors whose terms end at the Company's annual meeting of stockholders in 2029, and was not initially assigned to any Board committee. As a non-employee director, Mr. Daly will receive compensation under the Company's director compensation program, as revised from time to time. The filing states that current components of that program consist of cash retainers for Board and committee service, restricted stock and stock option awards, and that these components were described in the proxy statement for the 2026 Annual Meeting of Stockholders held on May 5, 2026. The filing states there are no arrangements or understandings under which Mr. Daly was elected as a director, and no related person transactions between the Company and Mr. Daly.

Sep 30, 2026
8-K
Material AgreementsFinancial EventsSecurities & Listing+1

Halozyme Therapeutics 8-K Report, Material Agreement (Sep 22, 2026)

On September 22, 2026, Halozyme Therapeutics, Inc. completed the sale of $1,500.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2033, including $200.0 million issued under the initial purchasers' option. The Company received net proceeds of approximately $1,471.1 million after discounts, commissions and estimated offering expenses. The notes were sold under Section 4(a)(2) of the Securities Act and Rule 144A to qualified institutional buyers, and are unsecured obligations that rank senior to subordinated indebtedness and equally with existing unsubordinated liabilities. Interest is payable semi-annually on April 1 and October 1, beginning April 1, 2027. The Company used approximately $187.5 million of the proceeds to fund capped call transactions, which are intended to reduce potential dilution on conversion, subject to a cap price of approximately $208.39 per share. It also expects to use part of the proceeds to repurchase $151.7 million of its 0.25% convertible notes due 2027 and $220.0 million of its 1.00% convertible notes due 2028, for total repurchase costs of approximately $217.0 million and $435.5 million, respectively, including accrued interest. The remaining proceeds are intended for general corporate purposes, including working capital, capital expenditures, potential acquisitions and strategic transactions, and possible future note repurchases. The notes have an initial conversion rate of 7.1509 shares per $1,000 principal amount, equivalent to a conversion price of approximately $139.84 per share, and the Company may settle conversions in cash, shares, or a combination at its election. Conversion is permitted under specified conditions, including a share price test of 130% of the conversion price and at any time from April 1, 2033 until shortly before maturity. The notes are redeemable at the Company's option on or after October 7, 2030 subject to a share price condition, and a cleanup redemption is available if less than $100.0 million remains outstanding. Holders may require repurchase at par plus accrued interest upon a fundamental change.

Sep 22, 2026
8-K
Other EventsExhibits & Filings

Halozyme Therapeutics 8-K Report, Corporate Update (Sep 18, 2026)

On September 17, 2026, Halozyme Therapeutics, Inc. priced an upsized private offering of $1.3 billion aggregate principal amount of 1.50% convertible senior notes due October 1, 2033. The offering was increased from the previously announced $1.05 billion, and the initial purchasers received a 13-day option to buy up to an additional $200 million of notes. The notes are senior, unsecured obligations, and the company expects to close the offering on September 22, 2026. The company expects net proceeds of approximately $1.275 billion, or approximately $1.471 billion if the option is exercised in full. The initial conversion rate is 7.1509 shares per $1,000 principal amount, equal to an initial conversion price of approximately $139.84 per share, a conversion premium of approximately 27.5% above the $109.68 closing price on September 17, 2026. The company will settle conversions in cash and, if applicable, shares, at its election. The company plans to use approximately $162.5 million of the net proceeds to fund capped call transactions, with an initial cap price of approximately $208.39 per share, a premium of approximately 90.0% above the September 17, 2026 last reported sale price. Concurrently, the company intends to repurchase $151.7 million principal amount of its 0.25% convertible senior notes due 2027 for a total cost of approximately $217.0 million, including accrued interest, and $220.0 million principal amount of its 1.00% convertible senior notes due 2028 for a total cost of approximately $435.5 million, including accrued interest. The remaining proceeds are intended for general corporate purposes, including working capital, capital expenditures, potential acquisitions and strategic transactions, and future note repurchases or repayment. The filing notes that the note repurchases and related hedging activity by counterparties and holders could affect the market price of the common stock and the notes.

Sep 18, 2026
8-K
Other EventsExhibits & Filings

Halozyme Therapeutics 8-K Report, Corporate Update (Sep 16, 2026)

Halozyme Therapeutics, Inc. (Nasdaq: HALO) announced on September 16, 2026 that it intends to offer, subject to market conditions and other factors, $1.05 billion aggregate principal amount of convertible senior notes due 2033. The company also expects to grant the initial purchasers a 13-day option to buy up to an additional $150 million of the notes. The notes are being offered only to qualified institutional buyers under Rule 144A, and the filing states they will be senior, unsecured obligations that accrue interest payable semi-annually and mature on October 1, 2033. Conversions will be settled in cash and, if applicable, shares of common stock, at the company's election. The initial conversion rate, interest rate and other terms will be set at pricing. Halozyme states it expects to use a portion of the net proceeds to fund the cost of capped call transactions and to repurchase portions of its outstanding 0.25% convertible senior notes due 2027 and 1.00% convertible senior notes due 2028 through privately negotiated transactions. The remaining proceeds are intended for general corporate purposes, including working capital, capital expenditures, potential acquisitions and strategic transactions, and possible future note repurchases or repayment of the notes at maturity or upon early optional redemption. The filing notes that the note repurchases and related hedging activity by counterparties could affect the market price of the common stock and the notes, and the capped calls are generally expected to reduce potential dilution from conversions. The filing is a notice of a proposed offering and does not state final pricing, size of the option exercise or closing results. The accompanying press release also describes the company's ENHANZE drug delivery technology, Hypercon and Surf Bio hyperconcentration technologies, and its Hylenex and XYOSTED commercial products.

Sep 16, 2026
8-K
Leadership Changes

Halozyme Therapeutics 8-K Report, Executive Changes (Aug 18, 2026)

Halozyme Therapeutics, Inc. filed a Form 8-K dated August 18, 2026 under Item 5.02 to report the election of a new director. On August 14, 2026, Dannielle Appelhans was elected to the Board of Directors. She was placed in the class of directors whose terms end at the Company's 2028 annual meeting of stockholders and was not initially assigned to any Board committee. Ms. Appelhans will be compensated under the Company's director compensation program for non-employee directors, as revised from time to time. The filing states that this program currently consists of cash retainers for Board and committee service, restricted stock and stock option awards. The current components were described in the proxy statement for the 2026 Annual Meeting of Stockholders, held on May 5, 2026. The filing states there are no arrangements or understandings under which Ms. Appelhans was elected, and no related person transactions between the Company and her. The filing reports no financial results, guidance, or other operational developments.

Aug 18, 2026
8-K
Earnings & ResultsExhibits & Filings

Halozyme Therapeutics 8-K Report, Financial Results (Aug 6, 2026)

Halozyme Therapeutics, Inc. reported record second-quarter 2026 results in a press release furnished as Exhibit 99.1 to this Form 8-K. Total revenue was $481.0 million, up from $325.7 million in the second quarter of 2025, driven by royalty revenue of $307.7 million (compared with $205.6 million) and higher product sales. Net income was $229.9 million, or $1.90 per diluted share (GAAP), compared with $165.2 million, or $1.33, a year earlier. Non-GAAP diluted EPS was $2.28, compared with $1.54, and adjusted EBITDA was $328.8 million, compared with $225.5 million. The company raised its full-year 2026 guidance. Total revenue is now expected at $1.835 billion to $1.910 billion (previously $1.710 billion to $1.810 billion), royalty revenue at $1.220 billion to $1.245 billion, adjusted EBITDA at $1.225 billion to $1.280 billion, and non-GAAP diluted EPS at $8.65 to $9.00. The guidance includes approximately $60 million of new Hypercon and Surf Bio investments. Management stated that the company has signed five new ENHANZE and Hypercon collaborations year to date, exceeding its goal of three for the full year. On capital allocation, Halozyme repurchased $333 million of shares in the second quarter at an average price of $69.30 under its May 2026 and February 2024 programs. The May 2026 program authorizes up to $1.0 billion of repurchases through December 31, 2028, with an expectation of at least $400 million of buybacks in 2026. Cash, cash equivalents, restricted cash and marketable securities totaled $231.9 million at June 30, 2026, and total debt-related balances on the balance sheet include $209.0 million current and $1.94 billion long-term.

Aug 6, 2026
8-K
Leadership Changes

Halozyme Therapeutics 8-K Report, Executive Changes (Jul 2, 2026)

Halozyme Therapeutics, Inc. filed a Current Report on Form 8-K dated June 30, 2026 (filed July 2, 2026) under Item 5.02, which covers departures of directors or certain officers, appointments, and compensatory arrangements. The filing states that on June 30, 2026, the company announced an update to its senior management structure. The same announcement disclosed the departure of Cortney Caudill as Senior Vice President, Chief Operating Officer. The company thanked Ms. Caudill for her contributions during her tenure. The filing does not describe the reasons for the departure, a successor, or any compensation or separation terms. The filing contains no financial results, financial statements, or quantitative figures. It is signed by Darren Snellgrove, Senior Vice President and Chief Financial Officer. For investors, the key item is the leadership change in the operations function and the broader senior management update.

Jul 2, 2026
8-K
Earnings & ResultsExhibits & Filings

Halozyme Therapeutics 8-K Report, Financial Results (May 11, 2026)

Halozyme Therapeutics, Inc. (Nasdaq: HALO) furnished a press release under Item 2.02 reporting first quarter 2026 results for the quarter ended March 31, 2026. Total revenue was $376.7 million, up 42% year over year from $264.9 million, driven by royalty revenue of $240.7 million (up 43% from $168.2 million) and product sales, net, of $130.4 million. GAAP net income was $150.0 million and GAAP diluted EPS was $1.22, compared with $0.93 a year earlier. Non-GAAP diluted EPS was $1.60, versus $1.11. Adjusted EBITDA was $229.5 million, including $11.2 million of intellectual property litigation costs tied to the company's patent case against Merck. Cash, cash equivalents, restricted cash and marketable securities rose to $320.9 million at March 31, 2026, from $145.4 million at December 31, 2025, which the company attributed primarily to operating cash generation. The company reiterated its full-year 2026 guidance: total revenue of $1.710 to $1.810 billion, royalty revenue of $1.130 to $1.170 billion, adjusted EBITDA of $1.125 to $1.205 billion, and non-GAAP diluted EPS of $7.75 to $8.25. The guidance includes approximately $60 million of investment related to new Hypercon and Surf Bio activities. The company also announced a new share repurchase program of up to $1 billion of common stock through December 31, 2028, with at least $400 million expected to be repurchased in 2026. The quarter also featured new partnering activity: a Vertex Hypercon agreement with a $15 million upfront payment, a GSK ENHANZE multi-target collaboration, and an Oruka Hypercon agreement. The company also highlighted FDA approval of VYVGART Hytrulo for all serotypes of generalized myasthenia gravis and positive Phase 3 data in ocular myasthenia gravis. The filing notes that results and partner milestones are forward-looking in part and subject to risks described in the company's Form 10-K and Form 10-Q.

May 11, 2026
8-K
Shareholder Matters

Halozyme Therapeutics 8-K Report, Shareholder Vote Results (May 7, 2026)

Halozyme Therapeutics, Inc. held its Annual Meeting of Stockholders on May 5, 2026. Of the 118,474,300 shares of common stock outstanding as of the record date, 104,138,244 shares were represented at the meeting. The filing states that stockholders considered three proposals, each described in the Company's definitive proxy statement filed with the SEC on March 23, 2026. Stockholders elected two Class I directors, Bernadette Connaughton and Matthew L. Posard, to three-year terms expiring at the 2029 Annual Meeting. Each received affirmative votes from more than a majority of outstanding shares. Stockholders also approved, on an advisory basis, the compensation of the Company's named executive officers, with 84,682,518 votes for, 9,311,426 against, 255,081 abstentions and 9,889,219 broker non-votes. Stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, with 103,197,579 votes for, 849,433 against and 91,232 abstentions. The filing reports no broker non-votes for this proposal.

May 7, 2026
8-K
Leadership ChangesExhibits & Filings

Halozyme Therapeutics 8-K Report, Executive Changes (Apr 30, 2026)

Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced on April 30, 2026 that Darren Snellgrove has been appointed Chief Financial Officer, effective June 8, 2026, reporting to President and CEO Helen Torley. Mr. Snellgrove, age 52, most recently served as Vice President, Investor Relations at Johnson & Johnson since May 2025, and previously served as CFO of J&J's Pharmaceutical sector from August 2021 to May 2025. David Ramsay, the current Interim CFO, will move to an advisory role effective June 8, 2026 to assist during a brief transition period. Compensation terms include an annual base salary of $670,000, a bonus target of 50% of base salary (prorated in 2026), and a 2027 long-term incentive award with a minimum total grant date value of $4,000,000. On joining, he will receive equity awards with a total grant date value of $7,200,000, consisting of $3,200,000 in restricted stock units intended to make him whole for forfeited equity from J&J, vesting one-third annually over three years, and $4,000,000 in stock options. He will also receive a $350,000 sign-on cash bonus, partially subject to repayment if he leaves or is terminated for misconduct within 24 months. The filing also includes a press release describing the new CFO's responsibilities, which include capital allocation, corporate development and investor relations, and the company's stated aim of accelerating shareholder value creation. The filing reports no family relationships with directors or executive officers and no material related-party interest.

Apr 30, 2026
8-K
Corporate ChangesExhibits & Filings

Halozyme Therapeutics 8-K Report, Bylaw Amendment (Apr 24, 2026)

Halozyme Therapeutics, Inc. filed a Current Report on Form 8-K on April 24, 2026 to disclose amendments to its Bylaws adopted by the Board of Directors on April 22, 2026. The filing does not report financial results, financial figures, or operating developments. The first amendment revises Section 2.5 of the Bylaws to provide that directors may be removed from office at any time, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of the directors. The second amendment revises Section 1.12 to clarify that any action required or permitted to be taken at an annual or special meeting of stockholders may not be taken without a meeting, consistent with Article FIFTH of the Certificate of Incorporation. The full amended Bylaws are filed as Exhibit 3.1, and the filing includes the Cover Page Interactive Data File (Exhibit 104) formatted as inline XBRL.

Apr 24, 2026
8-K
Leadership ChangesExhibits & Filings

Halozyme Therapeutics 8-K Report, Executive Changes (Mar 12, 2026)

Halozyme Therapeutics, Inc. (NASDAQ: HALO) filed a Form 8-K on March 12, 2026 to announce the appointment of David Ramsay as Interim Chief Financial Officer, effective March 23, 2026. Mr. Ramsay will oversee all financial operations while the company continues its active search for a permanent CFO, for which it has engaged a leading executive search firm. He will remain in the role until a permanent CFO is appointed. Mr. Ramsay previously served as the Company's CFO from 2003 to 2009 and again from 2013 to 2015, and as Vice President, Corporate Development from 2009 to 2013. Since April 2017 he has served on the board of Savara Inc., and he was previously Senior Vice President and CFO of Bonti, Inc. until its acquisition by Allergan plc in October 2018. The filing states that he has no family relationships with any director or executive officer and no material interest in any Company transaction. Compensation under the arrangement is a monthly salary of $50,000, plus an initial grant of 10,000 restricted stock units (RSUs) vesting on June 30, 2026, and an additional 2,500 RSUs granted if he is still Interim CFO on July 1, 2026. Both grants fall under the 2021 Stock Plan and carry a one-year holding period after vesting. The filing also notes that the forward-looking statements in the press release cite potential delays in hiring a permanent CFO as a risk factor.

Mar 12, 2026
8-K
Earnings & ResultsExhibits & Filings

Halozyme Therapeutics 8-K Report, Financial Results (Feb 17, 2026)

Halozyme Therapeutics, Inc. (NASDAQ: HALO) furnished a press release under Item 2.02 reporting fourth-quarter and full-year 2025 results. Full-year total revenue was $1,396.6 million, up 38% from $1,015.3 million in 2024, driven by royalty revenue of $867.8 million (up 52% from $571.0 million) and higher product sales. Net income for the full year was $316.9 million, compared with $444.1 million in 2024. The results include $284.9 million of acquired in-process R&D expense tied to the Surf Bio acquisition, which drove a fourth-quarter net loss of $141.6 million. Fourth-quarter total revenue was $451.8 million, up 52% from $298.0 million. Full-year GAAP diluted EPS was $2.56 versus $3.43 in 2024, and non-GAAP diluted EPS was $4.15 versus $4.23. The company reported that cash, cash equivalents, restricted cash and marketable securities were $145.4 million at December 31, 2025, compared with $596.1 million a year earlier, mainly reflecting cash used for the Elektrofi and Surf Bio acquisitions and share repurchases, partly offset by net proceeds from $1.5 billion of convertible notes issued in November 2025 (two $750.0 million tranches due 2031 and 2032). The company also amended its credit agreement, raising its revolving facility from $575.0 million to $750.0 million. Halozyme reiterated its 2026 guidance: total revenue of $1.710 to $1.810 billion (22% to 30% growth), royalty revenue of $1.130 to $1.170 billion (30% to 35% growth), adjusted EBITDA of $1.125 to $1.205 billion (71% to 83% growth), and non-GAAP diluted EPS of $7.75 to $8.25 (87% to 99% growth). The guidance includes approximately $60 million of investment related to Hypercon and Surf Bio. Management stated it expects royalty revenue to exceed $1 billion in 2026 and has a "clear line of sight" to more than $2 billion in total revenue by 2028.

Feb 17, 2026
8-K
Earnings & ResultsExhibits & Filings

Halozyme Therapeutics 8-K Report, Financial Results (Jan 28, 2026)

Halozyme Therapeutics, Inc. (Nasdaq: HALO) furnished an Item 2.02 Form 8-K on January 28, 2026, disclosing preliminary, unaudited 2025 results and raised 2026 and multi-year guidance. For the twelve months ended December 31, 2025, the company estimates total revenue of $1,385 million to $1,400 million, royalty revenue of $865 million to $870 million, product sales of $372 million to $377 million, and collaboration revenue of $148 million to $153 million. The company states that royalty revenue growth is expected to exceed 50% year over year in 2025, with total revenue growth of 36% to 38% and royalty revenue growth of 51% to 52%. For 2026, Halozyme raised its guidance: total revenue of $1,710 million to $1,810 million (previously $1,430 million to $1,530 million), royalty revenue of $1,130 million to $1,170 million (previously $900 million to $940 million), adjusted EBITDA of $1,125 million to $1,205 million (previously $1,000 million to $1,080 million), and non-GAAP diluted EPS of $7.75 to $8.25 (previously $6.50 to $7.00). The company notes that these figures include approximately $60 million of Hypercon and Surf Bio investment not included in prior guidance. Management said projected 2026 royalty revenue of more than $1 billion is one year earlier than previously projected. The company also disclosed that it acquired Surf Bio, Inc. in December 2025 for an upfront payment of $300 million, plus up to $100 million in milestone payments, for total consideration of up to $400 million. The filing emphasizes that the preliminary 2025 estimates are subject to completion of financial close procedures and may vary materially from the results in the forthcoming Form 10-K. The Item 2.02 information is furnished, not filed.

Jan 28, 2026
8-K
Leadership Changes

Halozyme Therapeutics 8-K Report, Executive Changes (Dec 9, 2025)

Halozyme Therapeutics, Inc. disclosed under Item 5.02 that its Compensation Committee approved a one-time performance-based restricted stock unit grant (the "PSU Grant") for Dr. Helen Torley, Chief Executive Officer, on December 4, 2025. The award was made under the Company's 2021 Stock Plan and has a grant date fair value of $10 million, determined under U.S. GAAP using a Monte Carlo valuation model. The grant is intended to retain Dr. Torley and incentivize her to drive growth and profitability during what the filing calls the Company's "next stage of growth." The number of shares that can vest depends on the average closing price of the common stock over 20 consecutive trading days during a four-year performance period following the grant date. Vesting ranges from 50% of the target shares at an average price of $115.00 to 200% at $170.00, with 100% at $130.00 and 150% at $145.00. If the average price never reaches $115.00, no shares will be eligible to vest. Earned shares also require Dr. Torley's continued employment through the fourth anniversary of the grant date, subject to exceptions in the award agreement. The filing states that voluntary resignation or retirement before the vesting date will result in forfeiture of all performance-based vested shares. The full award agreement is to be filed as an exhibit to the Company's Form 10-K for the fiscal year ending December 31, 2025.

Dec 9, 2025
8-K
Leadership Changes

Halozyme Therapeutics 8-K Report, Executive Changes (Dec 8, 2025)

Halozyme Therapeutics, Inc. filed this Form 8-K on December 8, 2025 under Item 5.02 to report a board change. On December 4, 2025, James Lang was elected to the Company's Board of Directors. He was elected to the class of directors whose terms end at the 2027 annual meeting of stockholders, and he was not initially assigned to any Board committee. Mr. Lang will be compensated under the Company's director compensation program applicable to all non-employee directors, as revised from time to time. The filing states that this program currently consists of cash retainers for Board and committee service, restricted stock, and stock option awards. The filing refers to the program components as described in the proxy statement for the 2025 Annual Meeting of Stockholders, held on May 1, 2025. The filing states that there are no arrangements or understandings under which Mr. Lang was elected, and no related person transactions between the Company and Mr. Lang. This is a governance update with no financial figures disclosed in the filing.

Dec 8, 2025
8-K
Leadership Changes

Halozyme Therapeutics 8-K Report, Executive Changes (Nov 24, 2025)

Halozyme Therapeutics, Inc. disclosed under Item 5.02 that Nicole LaBrosse, Senior Vice President and Chief Financial Officer, will continue to serve as CFO until the earliest of the hiring of a new chief financial officer, March 30, 2026, or an earlier date set by the Company (the "Separation Date"), and will then depart to pursue a new professional opportunity. The company had previously announced this transition plan. On November 18, 2025, the Company and Ms. LaBrosse entered into a Transition and Release Agreement. Subject to her compliance with its obligations and her execution of a release of claims, she will be eligible for a 2025 annual bonus at 120% of target-level individual performance, a cash severance payment under the Company's Severance Policy for a not-for-cause termination equal to her annual base salary (plus a pro-rated 2026 target bonus if separation occurs in 2026), and enhanced equity and benefits treatment. Specifically, awards that would have vested by February 28, 2026 vest on the Separation Date if separation occurs before that date, vested options get an extended exercise period, unvested options accelerate on a Change in Control within one year after separation, and COBRA coverage costs are covered for one year. The filing states that the full agreement will be filed as an exhibit to the Company's Form 10-K for the year ending December 31, 2025. For investors, the key items are the impending CFO departure, the defined separation timeframe, and the severance and equity terms that define the cost and retention implications of the transition.

Nov 24, 2025
8-K
Material AgreementsFinancial EventsSecurities & Listing+1

Halozyme Therapeutics 8-K Report, Material Agreement (Nov 12, 2025)

Halozyme Therapeutics, Inc. completed its previously announced sale of $1,500.0 million aggregate principal amount of convertible senior notes on November 12, 2025. The offering consisted of $750.0 million of 0% Convertible Senior Notes due 2031 and $750.0 million of 0.875% Convertible Senior Notes due 2032, each including $100.0 million of additional notes purchased through the initial purchasers' option. The company received net proceeds of approximately $1.47 billion, of which about $182.7 million was used to fund capped call transactions, and it paid approximately $1.020 billion in cash, including accrued interest, to repurchase portions of its outstanding 0.25% Convertible Senior Notes due 2027 and 1.00% Convertible Senior Notes due 2028 through privately negotiated transactions. The remaining proceeds are intended for general corporate purposes, including working capital, capital expenditures, potential acquisitions and strategic transactions, and potential future note repurchases. The notes are unsecured and rank effectively junior to secured indebtedness and structurally subordinated to liabilities of subsidiaries. The initial conversion rate is 11.4683 shares per $1,000 principal amount, equivalent to a conversion price of approximately $87.20 per share. The company may settle conversions in cash, shares, or a combination at its election. The 2031 notes carry no regular interest, while the 2032 notes pay 0.875% semi-annually beginning May 15, 2026. The company may not redeem the 2031 notes before February 20, 2029, or the 2032 notes before November 20, 2029. The capped call transactions have an initial cap price of $136.78 per share, which the filing states represents a 100% premium over the November 5, 2025 closing price for both series. Investors should note the holder protections in the indentures, including repurchase rights upon a fundamental change and cross-default provisions tied to indebtedness of at least $50.0 million. The notes were sold under Rule 144A to qualified institutional buyers and have not been registered under the Securities Act.

Nov 12, 2025
8-K
Other EventsExhibits & Filings

Halozyme Therapeutics 8-K Report, Corporate Update (Nov 7, 2025)

Halozyme Therapeutics, Inc. (NASDAQ: HALO) filed a Current Report on Form 8-K on November 7, 2025 to disclose, via Exhibit 99.1, its press release dated November 6, 2025 announcing the pricing of two convertible senior notes offerings. The Company priced $650.0 million aggregate principal amount of 0% convertible senior notes due 2031 (the 2031 Notes) and $650.0 million aggregate principal amount of 0.875% convertible senior notes due 2032 (the 2032 Notes), for a total of $1.3 billion before the initial purchasers' 13-day option to buy up to an additional $100.0 million of each series. The offering is being sold only to qualified institutional buyers under Rule 144A. Both series have an initial conversion rate of 11.4683 shares per $1,000 principal amount, equal to an initial conversion price of approximately $87.20 per share, a conversion premium of approximately 27.5% over the $68.39 closing price on November 6, 2025. The Company will settle conversions in cash and/or shares at its election. The Company expects the net proceeds to be approximately $1.274 billion (or approximately $1.47 billion if the option is exercised in full). It expects to use about $182.7 million for capped call transactions, with a cap price of $136.78 per share (a 100% premium to the reference price), and about $1.020 billion to repurchase portions of its existing 0.25% convertible notes due 2027 and 1.00% convertible notes due 2028 through privately negotiated transactions, with approximately $1.019 billion in cash expected to be paid including accrued interest. The remainder is intended for general corporate purposes, including working capital, capital expenditures, potential acquisitions and strategic transactions, and future note repurchases. The filing notes that the note repurchases and related hedging activity by counterparties could affect the market price of Halozyme's common stock and the Convertible Notes, and could result in a higher effective conversion price. The Company expects the offering to close on November 12, 2025, subject to customary closing conditions.

Nov 7, 2025
8-K
Material AgreementsFinancial EventsOther Events+1

Halozyme Therapeutics 8-K Report, Material Agreement (Nov 5, 2025)

On November 5, 2025, Halozyme Therapeutics, Inc. entered into Amendment No. 3 to its Credit Agreement dated May 24, 2022. The amendment extended the maturity of the existing revolving credit facility and increased total revolving commitments to $750,000,000. The Amended Revolving Credit Facility matures on the earlier of November 5, 2030 and the Springing Revolver Maturity Date. As of November 5, 2025, after giving effect to the amendment, the company had $0 of outstanding borrowings under the Credit Agreement. The credit agreement requires a maximum consolidated net leverage ratio of 4.50 to 1.00 and a minimum consolidated interest coverage ratio of 3.00 to 1.00, measured at each fiscal quarter end. The net leverage covenant increases by 0.50 to 1.00, to no more than 5.00 to 1.00, for three fiscal quarters after a material acquisition. The same day, the company announced a proposed offering, subject to market conditions, of $650.0 million of convertible senior notes due 2031 and $650.0 million of convertible senior notes due 2032. The initial purchasers also have a 13-day option to buy up to an additional $100.0 million of each series. The notes are senior, unsecured obligations, with the 2031 Notes maturing February 15, 2031 and the 2032 Notes maturing November 15, 2032. The company intends to settle conversions in cash and, where applicable, shares of common stock, at its election. Net proceeds are expected to fund capped call transactions, privately negotiated repurchases of the company's outstanding 0.25% convertible senior notes due 2027 and 1.00% convertible senior notes due 2028, and general corporate purposes, including working capital, capital expenditures, potential acquisitions and strategic transactions. The filing states that the note repurchases and related hedging activity by counterparties could affect the market price of the common stock and the convertible notes, and could result in a higher effective conversion price for the new notes. The filing also notes that the notes have not been registered under the Securities Act and are being offered only to qualified institutional buyers under Rule 144A.

Nov 5, 2025
8-K
Earnings & ResultsLeadership ChangesExhibits & Filings

Halozyme Therapeutics 8-K Report, Financial Results (Nov 3, 2025)

Halozyme Therapeutics, Inc. reported record third-quarter 2025 results and raised its 2025 financial guidance. Total revenue for the quarter was $354.3 million, up 22% year-over-year from $290.1 million, driven by royalty revenue of $236.0 million, up 52% from $155.1 million. Net income was $175.2 million, compared to $137.0 million a year earlier, and GAAP diluted EPS was $1.43 versus $1.05. Non-GAAP diluted EPS was $1.72, compared to $1.27. Adjusted EBITDA was $248.2 million, compared to $183.6 million in the prior-year quarter. Cash, cash equivalents and marketable securities totaled $702.0 million at September 30, 2025. For full-year 2025, the company now expects total revenue of $1,300 million to $1,375 million, royalty revenue of $850 million to $880 million, adjusted EBITDA of $885 million to $935 million, and non-GAAP diluted EPS of $6.10 to $6.50. These ranges are each raised from the prior guidance issued August 5, 2025. The filing also discloses a CFO transition. Nicole LaBrosse, Senior Vice President and Chief Financial Officer, will remain CFO until the earlier of the hiring of a successor or March 30, 2026, and then depart for a new professional opportunity. The company has begun an external search for her successor. The filing states her departure is not the result of any disagreement with the auditors or the company. The company also disclosed a pending acquisition of Elektrofi, Inc. for $750 million in upfront consideration plus up to three $50 million milestone payments, expected to close in the fourth quarter of 2025.

Nov 3, 2025
8-K
Regulation FDExhibits & Filings

Halozyme Therapeutics 8-K Report, Regulation FD Disclosure (Oct 14, 2025)

Halozyme Therapeutics, Inc. filed this Form 8-K on October 14, 2025 under Item 7.01 (Regulation FD Disclosure) to publish a position statement (Exhibit 99.1) on CMS's final IPAY 2028 guidance for Medicare Part B price negotiations under the Inflation Reduction Act. The statement covers the company's long-term projections of U.S. Medicare Part B spend as a percentage of total ENHANZE® partner product subcutaneous sales. The information is furnished, not filed, for purposes of Section 18 of the Exchange Act. The company's central message is that the final guidance has zero to minimal impact on its future partner royalties. CMS declined to change its fixed combination drug policy for initial price applicability year 2028 and said it would consider a rulemaking addressing the issue beginning in price applicability year 2029. Halozyme projects zero royalty revenue impact in 2028 and zero to minimal impact in 2029 through 2031 and through at least 2035. The filing attributes these projections to orphan drug exclusions under the One Big Beautiful Bill Act, the potential exclusion of drugs facing biosimilar launches, and the treatment of Darzalex Faspro and Opdivo as orphan-designated products. The statement also cites a 2025 Journal of Medical Economics study reporting Medicare savings from subcutaneous delivery for 5 of 7 biologic drugs compared with intravenous delivery, and an Oncology and Therapy study in which 89.6% of surveyed patients preferred subcutaneous delivery versus 5.5% for IV. The filing describes these as supporting evidence rather than a new financial result.

Oct 14, 2025
8-K
Leadership Changes

Halozyme Therapeutics 8-K Report, Executive Changes (Oct 6, 2025)

Halozyme Therapeutics, Inc. filed this Current Report on Form 8-K under Item 5.02, reporting executive leadership changes. On October 1, 2025, Cortney Caudill was appointed Senior Vice President, Chief Operating Officer, effective immediately. She had already served as the Company's Senior Vice President, Chief Operations Officer since October 2023, so the change is a promotion within the existing executive team rather than an external hire. The filing sets out Ms. Caudill's compensation in her new role. Her initial annual base salary as Chief Operating Officer is $600,000, and she is eligible to participate in the Company's executive officer incentive plans with a 2025 bonus target equal to 50% of base salary. She will also receive an equity award valued at $500,000 in connection with the appointment, split 50% stock options and 50% restricted stock units, vesting under the Company's standard four-year schedule. She will be eligible for long-term incentive awards under the Compensation Committee's practices for executive officers. The filing states that Ms. Caudill has no family relationships with any director or executive officer and no direct or indirect material interest in any transaction in which the Company is a participant. Her prior experience includes Aeglea Biotherapeutics, where she most recently served as Chief Product Officer, and several life sciences operational roles from 2002 to 2018.

Oct 6, 2025
8-K
Material AgreementsExhibits & Filings

Halozyme Therapeutics 8-K Report, Material Agreement (Oct 3, 2025)

On September 30, 2025, Halozyme Therapeutics, Inc. entered into an Agreement and Plan of Merger with Elektrofi, Inc., Erraid Merger Sub Inc. (a wholly-owned Halozyme subsidiary), and Shareholder Representative Services LLC, solely in its capacity as Securityholders' Representative. Under the agreement, Merger Sub will merge into Elektrofi, which will survive as a wholly-owned subsidiary of Halozyme. Halozyme will pay aggregate upfront consideration of $750 million in cash, subject to customary adjustments for Elektrofi's debt, cash, transaction expenses and net working capital, plus up to three $50 million milestone payments contingent on three separate product regulatory approvals. A portion of Elektrofi employee stock options will be assumed by Halozyme and converted into options to acquire Halozyme common stock, which will reduce the cash portion of the Merger Consideration. The merger is subject to customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The agreement includes customary termination rights, including if the merger is not consummated within twelve months of the agreement date, subject to a six-month extension in certain circumstances. If the agreement is terminated under certain circumstances, Halozyme must pay Elektrofi a $36 million reverse termination fee in cash. The filing attaches the Merger Agreement as Exhibit 2.1, with schedules omitted under Item 601(a)(5) of Regulation S-K and certain portions omitted under Item 601(b)(2), which Halozyme agrees to furnish to the SEC upon request. The filing also contains customary forward-looking statements, including risks that the transaction may not be consummated on the proposed terms or timing, or that required regulatory approvals may not be obtained or may be delayed.

Oct 3, 2025
8-K
Regulation FDExhibits & Filings

Halozyme Therapeutics 8-K Report, Regulation FD Disclosure (Oct 1, 2025)

Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced on October 1, 2025 that it has entered into a definitive agreement to acquire Elektrofi, Inc., a biopharmaceutical company with its Hypercon™ ultra-high concentration microparticle technology for biologics. The agreement, dated as of September 30, 2025, provides for an upfront payment of $750 million plus up to three $50 million milestone payments contingent on three separate product regulatory approvals. Both companies' Boards unanimously approved the transaction. Halozyme expects the deal to close in 4Q 2025, subject to HSR review and other customary conditions, and plans to finance the upfront payment with existing cash and its existing credit facility. Management states the transaction is expected to be less than 5% dilutive to Non-GAAP diluted EPS over the medium term, excluding potential milestone payments, and expects approximately $55 million of incremental operating expense in full-year 2026. Halozyme expects net leverage to rise to approximately 2X net debt-to-EBITDA immediately after closing, with rapid de-leveraging in subsequent quarters. The company reaffirmed its 2025 guidance ranges (last updated August 5, 2025), excluding the accounting treatment of the transaction, including total revenue of $1,275 million to $1,355 million and royalty revenue of $825 million to $860 million. Management frames the deal as a route to long-term royalty growth, with royalty revenue from Elektrofi's partners projected to begin as early as 2030 and intellectual property extending into the 2040s. Up to $275 million in potential development and commercial milestones from Elektrofi's two existing partner products is cited as supporting near-term de-risking, with two partners projected to begin Hypercon™ formulated product clinical development by year end 2026 or earlier.

Oct 1, 2025
8-K
Earnings & ResultsExhibits & Filings

Halozyme Therapeutics 8-K Report, Financial Results (Aug 5, 2025)

Halozyme Therapeutics, Inc. reported second-quarter 2025 results for the period ended June 30, 2025, with total revenue of $325.7 million, up 41% year over year from $231.4 million. Royalty revenue rose 65% to $205.6 million, driven mainly by DARZALEX SC, VYVGART Hytrulo and Phesgo. Net income was $165.2 million, compared with $93.2 million in the second quarter of 2024, and GAAP diluted EPS was $1.33, compared with $0.72. Adjusted EBITDA was $225.5 million, and Non-GAAP diluted EPS was $1.54. The company raised its full-year 2025 guidance for the second time this year. Total revenue is now expected at $1,275 million to $1,355 million (previously $1,200 million to $1,280 million), royalty revenue at $825 million to $860 million (previously $750 million to $785 million), adjusted EBITDA at $865 million to $915 million (previously $790 million to $840 million), and Non-GAAP diluted EPS at $6.00 to $6.40 (previously $5.30 to $5.70). The guidance reflects tariffs currently in effect. Capital allocation was active in the quarter. The company repurchased a total of $303.4 million of shares in the second quarter, including the $250 million program announced in May, and began a third $250 million tranche under its $750 million authorized program. Cash, cash equivalents and marketable securities were $548.2 million at June 30, 2025. The filing also notes a patent infringement lawsuit filed in April 2025 against Merck Sharp & Dohme Corp. over its MDASE drug delivery technology, with $2.6 million of related litigation costs recognized in the quarter.

Aug 5, 2025
8-K
Earnings & ResultsExhibits & Filings

Halozyme Therapeutics 8-K Report, Financial Results (May 6, 2025)

Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported financial results for the first quarter ended March 31, 2025, and raised its 2025 financial guidance ranges, as furnished in Exhibit 99.1 under Item 2.02. Total revenue was $264.9 million, up 35% year over year from $195.9 million, driven by royalty revenue of $168.2 million, up 39% from $120.6 million. Net income was $118.1 million versus $76.8 million, GAAP diluted EPS was $0.93 versus $0.60, and non-GAAP diluted EPS was $1.11 versus $0.79. Adjusted EBITDA was $162.0 million versus $115.7 million in the prior-year quarter. The company raised full-year 2025 guidance: total revenue of $1,200 million to $1,280 million (previously $1,150 million to $1,225 million), royalty revenue of $750 million to $785 million (previously $725 million to $750 million), adjusted EBITDA of $790 million to $840 million (previously $755 million to $805 million), and non-GAAP diluted EPS of $5.30 to $5.70 (previously $4.95 to $5.35). The guidance reflects tariffs currently implemented. The company also announced a second $250 million share repurchase under its $750 million program approved in February 2024, following the first $250 million accelerated share repurchase completed in March 2025. Cash, cash equivalents and marketable securities were $747.9 million at March 31, 2025. The filing also disclosed an April 2025 patent infringement lawsuit against Merck Sharp & Dohme Corp. in the U.S. District Court in New Jersey, alleging that Merck is using Halozyme's MDASE technology to develop subcutaneous Keytruda, and seeking damages and injunctive relief. Partner activity included several ENHANZE-related regulatory and commercial milestones, including FDA approval of VYVGART Hytrulo prefilled syringe for self-injection and a European Commission marketing authorization for SC RYBREVANT with ENHANZE, described as the 10th partner product with ENHANZE to be commercialized.

May 6, 2025
8-K
Shareholder Matters

Halozyme Therapeutics 8-K Report, Shareholder Vote Results (May 2, 2025)

Halozyme Therapeutics, Inc. held its Annual Meeting of Stockholders on May 1, 2025. Of the 123,533,310 shares of common stock outstanding as of the record date, 112,767,003 were represented at the meeting. Stockholders considered three proposals, each described in the company's definitive proxy statement filed with the SEC on March 18, 2025. Stockholders elected two Class III directors, Jeffrey W. Henderson and Helen I. Torley, to three-year terms expiring at the 2028 Annual Meeting. Henderson received 98,993,463 votes for and 3,298,117 against. Torley received 101,477,199 votes for and 816,675 against. Each director received affirmative votes from more than a majority of the outstanding shares. Stockholders also approved, on an advisory basis, the compensation of the named executive officers, with 98,252,464 votes for and 3,966,034 against. In addition, they ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with 112,028,211 votes for and 659,976 against. The filing reports voting results only. It does not describe any new corporate actions, financial results, or changes in governance beyond the matters voted on.

May 2, 2025
8-K
Leadership Changes

Halozyme Therapeutics 8-K Report, Executive Changes (Mar 21, 2025)

Halozyme Therapeutics, Inc. filed this Form 8-K to report a leadership change. On March 17, 2025, Michael J. LaBarre, Senior Vice President and Chief Technical Officer, notified the Company of his decision to retire, effective March 17, 2025. The Company thanked Mr. LaBarre for his many years of service and contributions to the Company's ENHANZE drug delivery technology. The filing is limited to this Item 5.02 disclosure (departure of certain officers). It does not disclose a successor appointment, financial results, or any financial figures, and it contains no financial metrics for investors to evaluate. For investors, the principal takeaway is the departure of a senior technical executive whose tenure was tied to the ENHANZE technology platform. The filing itself does not state any impact on operations, guidance, or succession plans.

Mar 21, 2025
8-K
Earnings & ResultsExhibits & Filings

Halozyme Therapeutics 8-K Report, Financial Results (Feb 18, 2025)

Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported fourth-quarter and full-year 2024 results in a press release furnished as Exhibit 99.1 under Item 2.02 of this 8-K, dated February 18, 2025. Total revenue for the fourth quarter was $298.0 million, up from $230.0 million a year earlier, driven by royalty revenue of $170.4 million (up 40% from $122.1 million) and higher collaborative-agreement revenue. For full-year 2024, total revenue was $1,015.3 million versus $829.3 million in 2023, and royalties were $571.0 million versus $447.9 million. Net income for the full year was $444.1 million and GAAP diluted EPS was $3.43; non-GAAP diluted EPS was $4.23. Adjusted EBITDA for the year was $632.2 million, compared with $426.2 million in 2023. The company reiterated its 2025 guidance, first given January 8, 2025: total revenue of $1,150 million to $1,225 million, royalty revenue of $725 million to $750 million, adjusted EBITDA of $755 million to $805 million, and non-GAAP diluted EPS of $4.95 to $5.35. Management said VYVGART Hytrulo is expected to become the largest dollar growth contributor to royalties in 2025. The company also noted four ENHANZE approvals in the U.S. and EU during 2024, five new ENHANZE nominations, a European ENHANZE patent extension to 2029, and an accelerated share repurchase of $250.0 million entered into in December 2024 under a $750 million program. At December 31, 2024, cash, cash equivalents and marketable securities totaled $596.1 million, up from $336.0 million at year-end 2023, and total stockholders' equity was $363.8 million. Long-term debt, net, was $1,505.8 million. The company said the increase in cash was primarily a result of cash generated from operations.

Feb 18, 2025
8-K
Leadership Changes

Halozyme Therapeutics 8-K Report, Executive Changes (Feb 13, 2025)

Halozyme Therapeutics, Inc. reported in this Form 8-K, filed February 13, 2025, that director Connie L. Matsui notified the Company on February 11, 2025, of her intention not to stand for reelection at the Company's 2025 annual meeting of stockholders. The filing is limited to this board change under Item 5.02(b), and it contains no financial results, guidance, or other operational or strategic disclosures. The Company and its Board of Directors thanked Ms. Matsui for her nearly 18 years of service, describing her counsel as sage advice. The filing states that her decision was not the result of any disagreement with the Company, any matter related to its operations, policies, practices or strategy, its management, or the Board. For investors, the disclosure is a routine board transition with no stated financial impact. It signals a board seat that will open after the 2025 annual meeting, and the filing does not name a successor or describe any related compensation arrangements.

Feb 13, 2025
8-K
Earnings & ResultsExhibits & Filings

Halozyme Therapeutics 8-K Report, Financial Results (Jan 8, 2025)

Halozyme Therapeutics, Inc. (NASDAQ: HALO) furnished a press release dated January 8, 2025 under Item 2.02 reiterating its 2024 financial guidance and raising its 2025 and multi-year guidance. The company's preliminary, unaudited 2024 estimates show total revenue of $970 to $1,020 million, royalty revenue of $550 to $565 million, net income of $419 to $443 million, adjusted EBITDA of $595 to $625 million, GAAP diluted EPS of $3.22 to $3.40, and non-GAAP diluted EPS of $4.00 to $4.20. The company notes these estimates are subject to completion of its financial close and could vary materially from final results in its Form 10-K. For 2025, Halozyme raised its guidance ranges: total revenue of $1,150 million to $1,225 million (16% to 23% growth over projected 2024), royalty revenue of $725 million to $750 million (30% to 35% growth), adjusted EBITDA of $755 million to $805 million (24% to 32% growth), and non-GAAP diluted EPS of $4.95 to $5.35 (21% to 30% growth). Prior 2025 ranges were total revenue of $1,095 million to $1,170 million, royalty revenue of $650 million to $675 million, adjusted EBITDA of $710 million to $760 million, and non-GAAP diluted EPS of $4.45 to $4.85. The company attributes the outlook mainly to VYVGART Hytrulo, Darzalex SC and Phesgo, with Ocrevus Zunovo, Tecentriq Hybreza and Opdivo Qvantig expected to contribute modestly in 2025. The company also announced a new $250 million accelerated share repurchase program under its previously announced $750 million share repurchase program. The 2025 EPS guidance does not consider the impact of potential future share repurchases.

Jan 8, 2025
8-K
Earnings & ResultsExhibits & Filings

Halozyme Therapeutics 8-K Report, Financial Results (Oct 31, 2024)

Halozyme Therapeutics, Inc. (NASDAQ: HALO) furnished a press release dated October 31, 2024 (Exhibit 99.1) reporting third quarter 2024 results for the period ended September 30, 2024. Total revenue rose 34% year over year to $290.1 million, driven by royalty revenue growth and higher milestone revenue. Royalties were $155.1 million, up 36% from $114.4 million, primarily from DARZALEX SC, Phesgo and the prior-year launch of VYVGART Hytrulo. Net income was $137.0 million versus $81.8 million, GAAP diluted EPS was $1.05 versus $0.61, and non-GAAP diluted EPS was $1.27 versus $0.75. Adjusted EBITDA was $183.6 million versus $114.9 million a year earlier. The company raised its 2024 guidance ranges: total revenue of $970 million to $1,020 million (previously $935 million to $1,015 million), royalty revenue of $550 million to $565 million (previously $520 million to $555 million), adjusted EBITDA of $595 million to $625 million (previously $555 million to $615 million), and non-GAAP diluted EPS of $4.00 to $4.20 (previously $3.65 to $4.05). Cash, cash equivalents and marketable securities were $666.3 million at September 30, 2024, compared with $336.0 million at December 31, 2023. For partner activity, the release notes that argenx expanded its license agreement in September 2024 to four additional targets, for a total of six, with upfront payments of $7.5 million per target ($30.0 million total). ViiV added one undisclosed target, and the FDA approved OCREVUS ZUNOVO and TECENTRIQ HYBREZA with ENHANZE in September 2024.

Oct 31, 2024
8-K
Earnings & ResultsExhibits & Filings

Halozyme Therapeutics 8-K Report, Financial Results (Aug 6, 2024)

Halozyme Therapeutics, Inc. furnished a press release (Exhibit 99.1) reporting second-quarter 2024 results for the period ended June 30, 2024. Total revenue was $231.4 million, up 5% from $221.0 million a year earlier. Royalty revenue rose 12% to $124.9 million, driven by Phesgo, the launch of VYVGART Hytrulo and the U.S. launch of Teriparatide. Net income was $93.2 million, compared with $74.8 million, and GAAP diluted EPS was $0.72 versus $0.56. Adjusted EBITDA was $137.0 million, compared with $115.1 million, and non-GAAP diluted EPS was $0.91 versus $0.74. Cash, cash equivalents and marketable securities totaled $529.0 million at June 30, 2024, up from $336.0 million at December 31, 2023. The company reiterated its 2024 guidance, which was raised on June 6, 2024 following a new European patent covering the ENHANZE rHuPH20 product. Guidance calls for total revenue of $935 million to $1,015 million (13% to 22% growth), royalty revenue of $520 million to $555 million (16% to 24% growth), adjusted EBITDA of $555 million to $615 million (30% to 44% growth) and non-GAAP diluted EPS of $3.65 to $4.05 (32% to 46% growth). The new European patent maintains the original royalty rate on DARZALEX SC sales in 37 European countries until March 2029. Royalties on DARZALEX SC were temporarily lowered in Europe between March and June 2024 before the patent was issued. The company also completed a $250 million accelerated share repurchase in June 2024, retiring 6.5 million shares at $38.35 per share, which concluded a December 2021 program totaling 19.1 million shares repurchased at an average of $39.31 per share. Management pointed to upcoming partner regulatory events, including a PDUFA goal date of September 13, 2024 for Roche's ocrelizumab SC and a PDUFA goal date of December 29, 2024 for BMS's nivolumab SC.

Aug 6, 2024
8-K
Earnings & ResultsExhibits & Filings

Halozyme Therapeutics 8-K Report, Financial Results (May 7, 2024)

Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported first quarter 2024 results on May 7, 2024, as furnished in Exhibit 99.1 under Item 2.02. Total revenues were $195.9 million, up from $162.1 million in the first quarter of 2023, driven by royalty revenue of $120.6 million and higher milestone revenue. Net income was $76.8 million, or $0.60 GAAP diluted EPS, compared with $39.6 million, or $0.29, a year earlier. Non-GAAP diluted EPS was $0.79 versus $0.47, and EBITDA and Adjusted EBITDA were both $115.7 million versus $74.3 million. The company reiterated its 2024 guidance: total revenue of $915 million to $985 million, royalty revenue of $500 million to $525 million, Adjusted EBITDA of $535 million to $585 million, and Non-GAAP diluted EPS of $3.55 to $3.90. Cash, cash equivalents and marketable securities were $463.5 million at March 31, 2024, up from $336.0 million at December 31, 2023, which the company attributed primarily to cash generated from operations. Total stockholders' equity rose to $177.8 million from $83.8 million. Management highlighted partner milestones, including FDA acceptance of Bristol Myers Squibb's subcutaneous nivolumab with a PDUFA goal date of February 28, 2025 and a $15.0 million milestone payment, and argenx's VYVDURA approval in Japan with $14.0 million in total milestone payments. The company also referenced a $750 million share repurchase program announced in February 2024.

May 7, 2024
8-K
Shareholder MattersExhibits & Filings

Halozyme Therapeutics 8-K Report, Shareholder Vote Results (Apr 26, 2024)

On April 25, 2024, Halozyme Therapeutics, Inc. held its Annual Meeting of Stockholders, at which 115,681,780 of the 127,054,240 shares of common stock outstanding as of the record date were represented. Stockholders elected two Class II directors, Barbara Duncan and Mahesh Krishnan, M.D., to three-year terms expiring at the 2027 Annual Meeting. Duncan received 90,120,424 votes for and 15,016,536 against, while Krishnan received 103,968,663 votes for and 1,164,017 against. Dr. Krishnan was subsequently appointed by the Board to the Nominating and Corporate Governance Committee. Stockholders also approved three other proposals: an advisory vote on named executive officer compensation (102,860,435 for, 2,190,603 against), an amendment to the Amended and Restated Certificate of Incorporation reflecting Delaware law provisions on officer exculpation (91,512,252 for, 13,612,616 against), and the ratification of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024 (114,912,469 for, 647,868 against). The exculpation amendment became effective upon filing the Amended and Restated Certificate of Incorporation with the Delaware Secretary of State on April 25, 2024, a copy of which is filed as Exhibit 3.1. The filing is a routine governance disclosure. It reports the results of shareholder votes and a charter amendment, and it contains no financial results, guidance, or transaction disclosures. Details of each proposal are described in the company's definitive proxy statement filed March 15, 2024.

Apr 26, 2024
8-K
Earnings & ResultsExhibits & Filings

Halozyme Therapeutics 8-K Report, Financial Results (Feb 20, 2024)

Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported fourth quarter and full year 2023 results in a press release furnished as Exhibit 99.1 to this Item 2.02 filing. Fourth quarter 2023 total revenue was $230.0 million, up 27% year-over-year from $181.5 million, driven by royalty revenue of $122.1 million, higher bulk rHuPH20 sales, XYOSTED growth and higher milestone revenue. Full year 2023 total revenue was $829.3 million, up 26% from $660.1 million, and GAAP diluted EPS was $2.10 versus $1.44 in 2022, while non-GAAP diluted EPS was $2.77 versus $2.21. Full year 2023 net income was $281.6 million and operating income was $337.6 million. The company reiterated its 2024 guidance, issued January 17, 2024: total revenue of $915 million to $985 million, royalty revenue of $500 million to $525 million, adjusted EBITDA of $535 million to $585 million, and non-GAAP diluted EPS of $3.55 to $3.90. Management cited 2023 approvals and positive phase 3 readouts, including VYVGART Hytrulo in CIDP and subcutaneous ocrelizumab and nivolumab, as drivers of future revenue opportunities. Cash, cash equivalents and marketable securities totaled $336.0 million at December 31, 2023, down from $362.8 million a year earlier, mainly due to $400.0 million of share repurchases in 2023. The filing also discloses a new share repurchase program of up to $750 million, announced in February 2024, which follows an accelerated share repurchase agreement entered in November 2023 to complete the remaining $250.0 million of a prior $750 million program. The company's total stockholders' equity fell to $83.8 million at year-end 2023 from $169.8 million, and long-term debt, net, was $1.50 billion.

Feb 20, 2024
8-K
Earnings & Results

Halozyme Therapeutics 8-K Report, Financial Results (Jan 17, 2024)

Halozyme Therapeutics, Inc. hosted a financial update call on January 17, 2024 covering its patent portfolio, 2024 financial guidance and long-term financial outlook. In connection with that call, the company furnished preliminary, unaudited estimates for the twelve months ended December 31, 2023: revenue of $827 million to $832 million and royalties of $445 million to $450 million. Net income is estimated at $292 million to $297 million, EBITDA at $435 million to $440 million, and Adjusted EBITDA at $425 million to $430 million. On a per-share basis, the company estimates 2023 GAAP diluted EPS of $2.18 to $2.21 and Non-GAAP diluted EPS of $2.77 to $2.80, based on 134.2 million diluted shares. The reconciliations show the Non-GAAP adjustments are driven largely by amortization of intangible assets ($0.55 per share), share-based compensation ($0.27 per share) and a gain on changes in fair value of a contingent liability ($0.10 per share), the latter tied to the September 2023 termination of the TLANDO license agreement, which also led to an inventory write-off and impairment of TLANDO product rights intangibles. The company cautions that these figures are subject to completion of its financial close and audit procedures, and that final results could vary materially. They are not a substitute for the Form 10-K for 2023 once filed. The estimates are furnished under Item 2.02 and are not deemed filed for purposes of Section 18 of the Exchange Act.

Jan 17, 2024
8-K
Earnings & ResultsExhibits & Filings

Halozyme Therapeutics 8-K Report, Financial Results (Nov 6, 2023)

Halozyme Therapeutics, Inc. reported third quarter 2023 results in a press release furnished as Exhibit 99.1 to this Item 2.02 filing. Total revenue was $216.0 million versus $209.0 million a year earlier, with royalty revenue at a record $114.4 million, up 15% year over year. GAAP net income was $81.8 million and GAAP diluted EPS was $0.61, compared with $0.44 in the prior-year quarter. Non-GAAP diluted EPS was $0.75 versus $0.74. EBITDA was $124.6 million and Adjusted EBITDA was $114.9 million. The company announced it will accelerate into 2023 the remaining $250 million under its $750 million share repurchase plan authorized in 2021, executing it through an accelerated share repurchase transaction with a financial institution, subject to market conditions. Management raised its 2023 EBITDA guidance to $430 million to $445 million from $420 million to $440 million and raised non-GAAP diluted EPS guidance to $2.70 to $2.80 from $2.65 to $2.75. Total revenue guidance of $825 million to $845 million was maintained, as was royalty revenue guidance of $445 million to $455 million. The release also highlighted partner developments, including a $8.0 million milestone tied to Roche's Tecentriq SC approval in Great Britain, a $5 million ViiV milestone, and a delay in the projected U.S. launch of Tecentriq SC to 2024 due to Roche's chemistry, manufacturing, and controls updates. The company also recorded a $2.5 million impairment of TLANDO product rights after Lipocine's license termination notice. Cash, cash equivalents and marketable securities were $483.3 million at September 30, 2023.

Nov 6, 2023
8-K
Other Events

Halozyme Therapeutics 8-K Report, Corporate Update (Sep 7, 2023)

Halozyme Therapeutics, Inc. filed this Form 8-K under Item 8.01 (Other Events) to disclose a delay in the projected U.S. launch timing for Tecentriq SC, with ENHANZE. On September 6, 2023, the Company was informed by its collaboration and license partner, F. Hoffmann-La Roche, Ltd. ("Roche"), that the launch will be delayed. The delay results from the need to update Tecentriq SC CMC processes. Roche expects these process updates to be completed in 2023 and expects them to support a potential U.S. launch of Tecentriq SC in 2024. The filing states there is no expected impact on ex-U.S. filings for Tecentriq SC. The filing's forward-looking statements caution that actual results may differ due to risks in pharmaceutical development and the regulatory approval process for collaboration products, and refer readers to the Risk Factors sections of the Company's periodic reports.

Sep 7, 2023
8-K
Earnings & ResultsExhibits & Filings

Halozyme Therapeutics 8-K Report, Financial Results (Aug 8, 2023)

Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported second quarter 2023 results on August 8, 2023, as furnished in Exhibit 99.1 under Item 2.02. Total revenue rose 45% year over year to $221.0 million from $152.4 million, with royalty revenue up 31% to a record $111.7 million, primarily attributable to subcutaneous DARZALEX (daratumumab). Product sales, net were $73.9 million, reflecting the Antares Pharma acquisition. GAAP diluted EPS was $0.56 versus $0.16 a year earlier, and non-GAAP diluted EPS was $0.74 versus $0.53. Net income was $74.8 million and EBITDA was $115.1 million, compared with $46.6 million in the prior-year quarter. The company raised its 2023 guidance. Total revenue is now expected at $825 million to $845 million, representing 25% to 28% growth, with the lower end raised from $815 million. Royalty revenue guidance was held at $445 million to $455 million. EBITDA guidance is $420 million to $440 million, up from $415 million to $440 million, and non-GAAP diluted EPS guidance was raised to $2.65 to $2.75 from $2.50 to $2.65, reflecting earlier share repurchases. Cash, cash equivalents and marketable securities were $348.3 million at June 30, 2023, down from $362.8 million at year-end 2022, mainly due to a $150.0 million stock repurchase in the first quarter. Partner developments cited in the release include FDA approval of argenx's VYVGART Hytrulo for generalized myasthenia gravis in June 2023, which triggered $33.0 million in milestone payments, positive ADHERE study data for CIDP, and Roche's OCARINA II Phase III trial of subcutaneous ocrelizumab meeting its endpoints. Management also pointed to possible FDA approval of Roche's subcutaneous atezolizumab later in 2023.

Aug 8, 2023
8-K
Earnings & ResultsExhibits & Filings

Halozyme Therapeutics 8-K Report, Financial Results (May 9, 2023)

Halozyme Therapeutics, Inc. reported first quarter 2023 results on May 9, 2023 in a press release furnished as Exhibit 99.1 under Item 2.02. Total revenue was $162.1 million, up 38% year over year from $117.3 million, with royalty revenue of $99.6 million, up 43% from $69.6 million. The increase was driven by higher royalties primarily from subcutaneous DARZALEX and the addition of product sales from the Antares Pharma acquisition. GAAP diluted earnings per share were $0.29 compared with $0.43 a year earlier, while non-GAAP diluted EPS was $0.47, flat with the prior-year period. Net income was $39.6 million versus $60.1 million, and operating income was $53.8 million versus $75.7 million. The year-over-year declines reflect a $25 million milestone payment in the first quarter of 2022 that did not recur, along with higher operating expenses. The company reiterated its 2023 guidance, calling for total revenue of $815 million to $845 million, royalty revenue of $445 million to $455 million, EBITDA of $415 million to $440 million, and non-GAAP diluted EPS of $2.50 to $2.65. Capital allocation was active in the quarter: Halozyme repurchased 4.2 million shares for $150.0 million at an average price of $36.01, bringing total repurchases under its $750 million three-year plan to 12.6 million shares for $500.0 million. In March 2023 it also converted its 2024 Convertible Notes in full for $13.5 million in cash and 288,886 shares of common stock. Cash, cash equivalents and marketable securities declined to $275.6 million at March 31, 2023 from $362.8 million at year-end 2022, mainly due to the buyback. The balance sheet shows total long-term debt, net, of $1.49 billion and total stockholders' equity of $65.9 million at March 31, 2023, down from $169.8 million at December 31, 2022, reflecting the repurchases. Partner milestones cited in the release include a Takeda sBLA approval for HYQVIA in pediatric primary immunodeficiency, a Roche BLA acceptance for SC atezolizumab with a PDUFA date of September 15, 2023, and an extended PDUFA date of June 20, 2023 for argenx's SC efgartigimod in generalized myasthenia gravis.

May 9, 2023
8-K
Shareholder Matters

Halozyme Therapeutics 8-K Report, Shareholder Vote Results (May 8, 2023)

Halozyme Therapeutics, Inc. filed this Form 8-K to report the results of its Annual Meeting of Stockholders, held on May 5, 2023. Of the 135,415,332 shares of common stock outstanding as of the record date, 124,528,163 shares were represented at the meeting. Stockholders considered four proposals, each described in the company's definitive proxy statement filed with the SEC on March 24, 2023. Stockholders elected three Class I directors, Bernadette Connaughton, Moni Miyashita and Matthew L. Posard, to three-year terms expiring at the 2026 Annual Meeting. Each received more affirmative votes than against, with Matthew L. Posard receiving 95,678,233 votes for and 16,598,543 against, the widest margin of opposition among the three. Stockholders also approved, on an advisory basis, the compensation of the named executive officers, with 107,628,112 votes for and 4,657,698 against. Stockholders also ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, with 123,271,829 votes for and 1,153,279 against. On the advisory vote on the frequency of future say-on-pay votes, 110,411,006 votes favored one year, 145,264 favored two years, and 1,760,124 favored three years. In light of these results and the Board's recommendation, the company will hold an annual advisory vote on executive compensation until the next required frequency vote.

May 8, 2023
8-K
Regulation FDExhibits & Filings

Halozyme Therapeutics 8-K Report, Regulation FD Disclosure (Mar 16, 2023)

Halozyme Therapeutics, Inc. (NASDAQ: HALO) furnished a Form 8-K on March 15, 2023 under Item 7.01 (Regulation FD) attaching a press release that updates investors on a decision by the Opposition Division of the European Patent Office concerning one of the Janssen Biotech co-formulation patents for DARZALEX (daratumumab) subcutaneous formulation. The Opposition Division issued an oral decision to revoke Janssen's European Patent EP3370770B1; a written decision is expected in the next several months, and an appeal would suspend the decision so the patent remains in force until the appeal is finally decided. Management stated the decision has no impact on current full-year 2023 revenue guidance, which was reiterated at $815 million to $845 million in total revenue and $445 million to $455 million in royalty revenue. The company also reaffirmed its projection of approximately $1 billion in total royalty revenue by 2027, and thereafter to at least 2030. Halozyme confirmed that co-formulation patents covering DARZALEX SC with ENHANZE do not extend the royalty step-down beyond 2024 in Europe and 2027 in the United States, and stated the decision does not affect composition of matter patents for ENHANZE in the U.S. and Europe. The filing is informational and is not deemed filed under Section 18 of the Exchange Act. Investors should note that the company's statements about the impact on royalties rely on management's outlook, and the forward-looking statements carry risks tied to the appeal process and licensee patent outcomes.

Mar 16, 2023
8-K
Other Events

Halozyme Therapeutics 8-K Report, Corporate Update (Mar 13, 2023)

Halozyme Therapeutics, Inc. filed this Form 8-K under Item 8.01 (Other Events) to address the closure of Silicon Valley Bank (SVB). The Federal Deposit Insurance Corporation (FDIC) was appointed receiver after the California Department of Financial Protection and Innovation closed SVB. A joint statement from the Department of the Treasury, Federal Reserve Board and FDIC on March 12, 2023 said depositors will have access to all of their money starting Monday, March 13. The Company states that it holds a small amount of cash in a deposit account at SVB, which as of March 10, 2023 did not exceed the $250,000 FDIC insured limit. SVB also acts as agent or asset manager for a majority of the Company's cash, cash equivalents and investments, and those funds are held in custodial accounts at independent financial institutions. The Company also disclosed that SVB is a lender under its $575 million revolving credit facility, with a commitment of approximately $39 million. The facility, a Credit Agreement dated May 24, 2022 and amended August 18, 2022, is administered by Bank of America, N.A. The Company reports no current withdrawals under the facility and no immediate intention to draw on it.

Mar 13, 2023
8-K
Leadership Changes

Halozyme Therapeutics 8-K Report, Executive Changes (Feb 23, 2023)

Halozyme Therapeutics, Inc. filed this Form 8-K dated February 22, 2023 to report a board change. On February 22, 2023, director James M. Daly notified the Company of his intention to resign from its Board of Directors, effective at the end of the 2023 calendar year. The filing states that Mr. Daly's resignation was not the result of any disagreement with the Company, any matter related to its operations, practices or strategy, its management, or the Board. The filing is limited to this Item 5.02(b) disclosure under Departure of Directors or Certain Officers. It contains no financial results, operating metrics, guidance, or transaction terms. It is signed by Mark Snyder, Senior Vice President, General Counsel and Corporate Secretary. For investors, the filing is a governance notice rather than a financial event. It signals a future board vacancy and that the departure was stated to be non-adversarial, but it does not indicate any effect on the Company's financial position or outlook.

Feb 23, 2023
8-K
Earnings & ResultsExhibits & Filings

Halozyme Therapeutics 8-K Report, Financial Results (Feb 21, 2023)

Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported financial results for the fourth quarter and full year ended December 31, 2022, in a press release furnished as Exhibit 99.1 under Item 2.02. Fourth-quarter total revenue was $181.5 million, up from $102.0 million a year earlier, with royalty revenue of $106.0 million. Full-year 2022 total revenue was $660.1 million, compared with $443.3 million in 2021, and full-year royalty revenue was $360.5 million. GAAP diluted earnings per share were $0.42 for the fourth quarter and $1.44 for the full year, while non-GAAP diluted EPS was $0.48 for the fourth quarter and $2.21 for the full year. The company attributed the growth to royalties tied to subcutaneous DARZALEX and the addition of Antares Pharma, which contributed product sales and amortization of intangibles of $43.1 million for the year. Halozyme reiterated its 2023 guidance, originally provided on January 10, 2023. It expects total revenue of $815 million to $845 million, royalty revenue of $445 million to $455 million, EBITDA of $415 million to $440 million, and non-GAAP diluted EPS of $2.50 to $2.65. Management pointed to two possible partner regulatory approvals in 2023 for ENHANZE-based products: SC efgartigimod for generalized myasthenia gravis and SC atezolizumab, which Roche's filing lists with a PDUFA date of September 15, 2023. The filing also notes that the efgartigimod PDUFA date was extended to June 20, 2023. On the balance sheet, cash, cash equivalents and marketable securities were $362.8 million at December 31, 2022, down from $740.9 million a year earlier, and long-term debt, net was $1.49 billion. The company completed a $110 million accelerated share repurchase in December 2022, has completed $350 million of a $750 million share repurchase plan, and plans to redeem all outstanding 1.25% convertible senior notes due 2024 on March 17, 2023.

Feb 21, 2023
8-K
Leadership Changes

Halozyme Therapeutics 8-K Report, Executive Changes (Feb 6, 2023)

Halozyme Therapeutics, Inc. filed this Form 8-K on February 6, 2023 to report a board change under Item 5.02(d). On February 3, 2023, Barbara Duncan was elected to the Board of Directors of Halozyme Therapeutics, Inc. as a director in the class whose term ends at the Company's 2024 annual meeting of stockholders. Ms. Duncan was initially assigned to the Audit Committee. She will receive compensation under the Company's director compensation program applicable to all non-employee directors, as revised from time to time. That program currently consists of cash retainers for Board and committee service and restricted stock awards, and its components were described in the proxy statement for the 2022 Annual Meeting of Stockholders held on May 5, 2022. The filing states that there are no arrangements or understandings under which Ms. Duncan was elected, and no related person transactions between the Company and her. The filing does not describe any financial results or other material business developments.

Feb 6, 2023
8-K
Earnings & ResultsRegulation FDExhibits & Filings

Halozyme Therapeutics 8-K Report, Financial Results (Jan 10, 2023)

Halozyme Therapeutics, Inc. furnished two documents on January 10, 2023: a press release providing 2023 financial guidance and outlook (Exhibit 99.1), and slides from its presentation at the 41st Annual J.P. Morgan Healthcare Conference (Exhibit 99.2). Both are furnished under Items 2.02 and 7.01 and are not deemed filed for purposes of Section 18 of the Exchange Act. The company reported that it projects record 2022 revenue of greater than $655 million and that it completed the acquisition of Antares Pharma. For 2023, Halozyme guided to total revenue of $815 million to $845 million, royalty revenue of $445 million to $455 million, EBITDA of $415 million to $440 million, and Non-GAAP diluted earnings per share of $2.50 to $2.65. The EBITDA guidance excludes amortization costs related to the Antares Pharma acquisition, and the EPS guidance does not consider potential future share repurchases. The company stated that its royalty growth is driven by DARZALEX SC and Phesgo, and by a full year of auto-injector royalty contribution. The company also outlined 2023 catalysts, including two expected ENHANZE subcutaneous approvals and launches by partners (SC efgartigimod and SC atezolizumab), four Phase 3 data readouts from partner products, and up to $150 million in share repurchases under the $750 million three-year plan authorized in December 2021. The filing notes that results could differ materially from forward-looking statements and refers readers to the company's Form 10-K and Form 10-Q filings for risk factors.

Jan 10, 2023
Page 1 of 6